Business · Companies · 2 hrs ago
Aroa Biosurgery expands US hospital reach through four purchasing group deals
Aroa Biosurgery is expanding sales of its soft tissue products in the United States, the world’s largest healthcare market.
The New Zealand company makes products used to support soft tissue regeneration.
It has agreements with all four major US hospital purchasing groups, known as Group Purchasing Organisations, or GPOs.
These groups negotiate purchasing terms for hospitals, and Aroa’s agreements cover up to 95% of US hospitals.
Aroa is using clinical evidence and lower-cost options to encourage hospitals to adopt its products, alongside its sales team’s relationships with healthcare providers.
Direct sales now make up 59% of the company’s business, and its US sales team has grown from around 10 people to more than 50.
The company is building on these partnerships and its clinical evidence to grow in the US market.
Aroa Biosurgery has agreements with all four major US hospital Group Purchasing Organisations, covering up to 95% of US hospitals.
The New Zealand-based company is using the agreements, clinical evidence and sales relationships to grow adoption of its soft tissue regeneration products in the US.
Aroa’s direct sales account for 59% of its business, and its US sales team has grown from around 10 members to more than 50.
The company received Vizient’s 2026 Innovative Technology Program Excellence Award for its collaboration with the group.
- Who
- Aroa Biosurgery, a New Zealand-based company, and the four major US Group Purchasing Organisations.
- What
- Aroa has secured agreements with all four major groups to support access to its soft tissue regeneration products.
- When
- The agreements were in place by November 6, 2026. The article does not give the dates they were signed.
- Where
- The United States.
- Why
- The agreements provide an entry point to hospitals and broader access for Aroa’s products. The company is also using clinical evidence and sales relationships to support growth.
This story does not have two clearly opposing sides.
Aroa Biosurgery was founded by CEO and managing director Dr Brian Ward.
The company listed on the ASX.
Aroa raised more than $47 million through an institutional placement and share purchase plan to fund its US growth strategy.
Stockhead reported that Aroa had agreements with all four major US Group Purchasing Organisations.
- GPO agreements
- All four major US groups: Vizient, HealthTrust, The Resource Group and Premier
- Hospital reach
- Up to 95% of US hospitals
- Direct sales
- 59% of Aroa’s business
- US sales team
- More than 50 members, up from around 10
- Award
- Vizient 2026 Innovative Technology Program Excellence Award
What people are saying
Relationships open doors, which you can build upon.
We originally had around 10 sales team members but that has grown to more than 50.
They were originally established to, in essence, take the contracting load off of the individual hospital or facility and aggregate hospitals into a group to achieve better standard pricing terms.